NASDAQ:ONCY Oncolytics Biotech Q2 2025 Earnings Report $1.13 -0.05 (-4.24%) Closing price 04:00 PM EasternExtended Trading$1.14 +0.02 (+1.33%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Oncolytics Biotech EPS ResultsActual EPS-$0.05Consensus EPS -$0.11Beat/MissBeat by +$0.06One Year Ago EPSN/AOncolytics Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncolytics Biotech Announcement DetailsQuarterQ2 2025Date8/8/2025TimeBefore Market OpensConference Call DateFriday, August 8, 2025Conference Call Time10:00AM ETUpcoming EarningsOncolytics Biotech's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Oncolytics Biotech Earnings HeadlinesOncolytics Biotech Inc.: Oncolytics Biotech Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to NevadaOctober 20 at 11:45 AM | finanznachrichten.deOncolytics Biotech entered into $50M at-the-market sales agreement with BTIGOctober 20 at 11:45 AM | msn.comThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted Cruz calling the White House a “mafia,” and even Trump’s approval rating slipping. But veteran analyst Porter Stansberry says this isn’t really about politics at all. It’s part of a much larger shift he calls The Final Displacement — a historic economic and social realignment already impacting millions of Americans. His new documentary explains what’s driving it and how to prepare before it accelerates further.October 20 at 2:00 AM | Porter & Company (Ad)Oncolytics Biotech Plans Jurisdiction Shift to NevadaOctober 20 at 9:51 AM | tipranks.comOncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to NevadaOctober 20 at 9:00 AM | prnewswire.comOncolytics Biotech Highlights Pelareorep’s Potential in Cancer TherapyOctober 10, 2025 | msn.comSee More Oncolytics Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncolytics Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncolytics Biotech and other key companies, straight to your email. Email Address About Oncolytics BiotechOncolytics Biotech (NASDAQ:ONCY) (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors. Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers. Collaborations with academic centers and pharmaceutical partners support ongoing research into optimal dosing regimens, novel combination strategies and biomarker identification. The company also maintains an early-stage pipeline of additional viral candidates aimed at broadening its platform of immune‐activating cancer therapies. Headquartered in Calgary, Alberta, with a research and development facility in Houston, Texas, Oncolytics sustains a presence in major North American life science hubs. The company’s infrastructure supports integrated translational research, process development and global clinical trial management, with a focus on advancing regulatory filings and securing strategic partnerships to accelerate commercialization. Under the leadership of President and Chief Executive Officer Brad Thompson, Oncolytics’ management team brings extensive experience in oncology drug development, virology and biopharmaceutical operations. The company remains committed to advancing its viral immunotherapy platform through rigorous clinical investigation and collaborative programs designed to address unmet needs in oncology.View Oncolytics Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Goldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Upcoming Earnings Intuitive Surgical (10/21/2025)Nasdaq (10/21/2025)Netflix (10/21/2025)PACCAR (10/21/2025)Texas Instruments (10/21/2025)Citigroup (10/21/2025)Chubb (10/21/2025)Capital One Financial (10/21/2025)Danaher (10/21/2025)Elevance Health (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
